The drug was administered continuously by I.V. for one week to 24 patients with either pancreatic or MSS CRC (both low tumour mutational burden types) and was shown to induce an integrated immune response https://www.pnas.org/content/early/2020/10/27/2013644117
Another trial testing a slightly different drug, chemo, and an anti-PD-1 (keytruda) showed activity in patients with pancreatic https://www.nature.com/articles/s41591-020-0880-x
Great! Thanks a lot!
I shortly discussed Plerixafor 5 years ago https://www.cancertreatmentsresearch.com/plerixafor-mozobil/